PO No :PO2912835867-962

Name : Mr.ASHU Client Name : TATA 1MG OKHLA

Age/Gender : 21/Male Registration Date : 09/Feb/2025 03:05PM
Patient ID : OKH1940550 Collection Date : 09/Feb/2025 01:51PM
Barcode ID/Order ID : D17290234 / 11944435 Report Date : 09/Feb/2025 07:29PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

Lipid Profile
Cholesterol - Total 166 mg/dL Low (desirable): < 200 Enzymatic
Moderate (borderline)
200–239
High: >/= 240
Triglycerides 67 mg/dL Normal: < 150, GPO, Trinder without
Borderline: 150 - 199, serum blank
High:200 - 499, Very
High >=500
Cholesterol - HDL 47 mg/dL Undesirable/high risk <40 Cholesterol Esterase
Desirable/low risk>=60
Cholesterol - LDL 105 mg/dL Desirable: <100 Calculated
Above desirable: 100 -
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 13 mg/dl <30 Calculated
Cholesterol : HDL Cholesterol 3.5 Ratio Desirable : 3.5-4.5 Calculated
High Risk : >5
LDL : HDL Cholesterol 2.22 Ratio Desirable : 2.5-3.0 Calculated
High risk : >3.5
Non HDL Cholesterol 119 mg/dl Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,
Very High: >= 220

Comment:

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 1 of 6
PO No :PO2912835867-962

Name : Mr.ASHU Client Name : TATA 1MG OKHLA

Age/Gender : 21/Male Registration Date : 09/Feb/2025 03:05PM
Patient ID : OKH1940550 Collection Date : 09/Feb/2025 01:51PM
Barcode ID/Order ID : D17290234 / 11944435 Report Date : 09/Feb/2025 07:29PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
•Lipid profile measurements in the same patient can show physiological & analytical variations. It is recommended that 3 serial
samples 1 week apart may be tested.
•Indians are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD); at a much earlier age and more severe
with high mortality. Dyslipidemia (abnormal lipid profile) is the major risk factor and found in almost 80% Indians.
•Total cholesterol is the total amount of cholesterol in blood comprising of HDL, LDL-C, and VLDL.
•LDL Cholesterol (LDL-C) or “bad”cholesterol contributes most significantly to atherosclerosis leading to heart disease or
stroke and is the primary target for reducing risk for cardiovascular disease.
•High-density lipoprotein (HDL) or “good” cholesterol can lower risk of heart disease and stroke.
•Triglyceride (TG) level also plays a major role in CVD. Indians are more prone to Atherogenic dyslipidemia, a condition
associated with high TG, low HDL-C and high LDL-C; this is associated with diabetes, metabolic syndrome and insulin resistance.
Hence high triglyceride levels also need to be treated.
•Non-HDL-Cholesterol (Non-HDLC) measures all plaque forming lipoproteins (e.g. remnants, LDL-C, VLDL, Lp(a), Apo-B).
Monitoring of Non-HDLC is important in patients with high TG (e.g. diabetics, obese persons) and those already on statin
therapy.
•Lipid Association of India (LAI-2020) recommends:-

Screening of all Indians above the age of 20 years for CVD risk factors, esp. lipid profile.
Identification of Risk factors: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age (<55 yrs
in males, <65 yrs in female), Smoking/tobacco use, High blood pressure, Low HDL (males <40 mg/dl and females
<50mg/dl).
Fasting lipid profile is not mandatory for screening. Both fasting and non-fasting lipid profiles are equally important for
managing Indian patients.
Non-HDLC should be calculated in every subject. LAI recommends LDL-C as the primary target and Non-HDLC as the co-
primary target for initiating drug therapy.
Lifestyle modifications are of first and foremost importance for management and prevention of dyslipidemia. Among low
risk groups, treatment is started only after 3 months of lifestyle changes.
Testing for Apolipoprotein B, hsCRP, Lp(a ) should be considered for patients in moderate risk group.
Newer treatment goals based on Risk Groups and values of LDL-C and Non-HDLC

New treatment goals by Lipid Association of India (2020)

CONSIDER THERAPY (cut-off level) TREATMENT GOALS
Risk groups LDL-C (mg/dL) Non-HDLC (mg/dL) LDL-C (mg/dL) Non-HDLC (mg/dL)
<50 <80
Extreme Risk Gp Cat. A ≥50 ≥80
(Optional ≤30) (Optional ≤60)
Extreme Risk Gp Cat. B >30 >60 ≤30 ≤60
Very High Risk ≥50 ≥80 <50 <80
High Risk ≥70 ≥100 <70 <100
Moderate Risk ≥100 ≥130 <100 <130
Low risk ≥130* ≥160* <100 <130
*After an adequate non-pharmacological intervention for at least 3 months

•As per NCEP Expert Panel (2011) guidelines, universal screening for dyslipidemia is recommended for children between 9
- 11 yrs (repeat at 17-21 yrs). Screening is not recommended before the age of 2yrs. Above the age of 2 yrs, selective screening

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 2 of 6
 PO No :PO2912835867-962

Name : Mr.ASHU Client Name : TATA 1MG OKHLA

Age/Gender : 21/Male Registration Date : 09/Feb/2025 03:05PM
Patient ID : OKH1940550 Collection Date : 09/Feb/2025 01:51PM
Barcode ID/Order ID : D17290234 / 11944435 Report Date : 09/Feb/2025 07:29PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
is done in children with family history of premature CVD or risk factors like obesity, diabetes, and hypertension.

Note: Reference Interval as per National Cholesterol Education Program (NCEP) Report.

LIVER FUNCTION TEST

Liver Function Test
Bilirubin-Total 0.78 mg/dL 0.3 – 1.2 Vanadate oxidation
Bilirubin-Direct 0.26 mg/dL 0.0-0.3 Vanadate oxidation
Bilirubin-Indirect 0.52 mg/dL 0.2-0.8 Calculated
Protein, Total 8.10 g/dL 5.7–8.2 Biuret
Albumin 5.10 g/dL 3.2-4.8 BCG Dye Binding
Globulin 3.0 g/dl 2.1 - 3.9 Calculated
A/G Ratio 1.70 Ratio 0.8 - 2.1 Calculated
Aspartate Transaminase (SGOT) 50 U/L <34 Modified IFCC
SGPT (Alanine Transaminase) 43 U/L 10-49 Modified IFCC
SGOT/SGPT 1.16 Ratio Calculated
Alkaline Phosphatase 85 U/L 46-115 IFCC Standardization
Gamma Glutamyltransferase (GGT) 15 U/L <73 Modified IFCC

Comment:

Raised ALT and AST indicate hepatocellular damage (e.g. viral or drugs etc). ALT is more liver-specific while AST is also
found in heart, skeletal muscle, and kidney. Mild elevation (less than twice normal) often resolves on its own. Fatty liver
disease (especially with metabolic syndrome) is a common cause in asymptomatic cases. Certain drugs (paracetamol,
statins), herbal supplements, energy drinks, and antibiotics may also affect liver function.
SGOT/SGPT Ratio: Typically <1 in healthy individuals (vary between 0.7-1.4; higher in women than men). High SGPT (ratio
<1) seen in acute or chronic hepatitis, autoimmune disorders, medications, toxins while ratio >1 indicates alcoholic
hepatitis, cirrhosis, metastasis or non-hepatic issues (hemolytic diseases, CVS disorders).
Elevated Alkaline Phosphatase and GGT: Suggest cholestatic diseases (e.g. bile duct obstruction, primary biliary
cirrhosis etc.) and can also be due to bone disease, pregnancy, chronic renal failure, malignancy, and congestive heart
failure.
High Bilirubin: Indicates jaundice due to increased RBC breakdown, liver damage (e.g., infections, toxins), or cholestasis

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 3 of 6
PO No :PO2912835867-962

Name : Mr.ASHU Client Name : TATA 1MG OKHLA

Age/Gender : 21/Male Registration Date : 09/Feb/2025 03:05PM
Patient ID : OKH1940550 Collection Date : 09/Feb/2025 01:51PM
Barcode ID/Order ID : D17290234 / 11944435 Report Date : 09/Feb/2025 07:29PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
(e.g., gallstones, tumors).
High Protein Levels: Seen in dehydration (e.g., severe vomiting, diarrhea) or increased production (e.g., inflammation,
hematopoietic neoplasms). Low protein and albumin: Result from impaired synthesis (liver disease), decreased intake,
tissue damage, malabsorption, or increased renal excretion.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 4 of 6
 PO No :PO2912835867-962

Name : Mr.ASHU Client Name : TATA 1MG OKHLA

Age/Gender : 21/Male Registration Date : 09/Feb/2025 03:05PM
Patient ID : OKH1940550 Collection Date : 09/Feb/2025 01:51PM
Barcode ID/Order ID : D17290234 / 11944435 Report Date : 09/Feb/2025 07:15PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method

Estradiol (E2) 24.7 pg/mL <11.8-48.9 CLIA

Comment:

Results Interpretation :

1. Serum Estradiol (E2) results must be interpreted according to the phase of the menstrual cycle.
2. Estradiol is the most potent natural estrogen in humans and regulates reproductive function in females, and, with
progesterone, maintains pregnancy.
3. Most estradiol is secreted by the ovaries (non-pregnant women), although the testes (in men) and adrenal cortex (in men and
women) secrete small amounts.
4. In normal non-pregnant women, estradiol synthesized by the ovary is the predominant source of both estrone (E1) and
estriol (E3).
5. During pregnancy, the placenta produces most of the circulating estradiol. If conception does not take place, estradiol falls
further to its lowest levels, and menses begins shortly thereafter.
6. At menopause, estradiol levels remain low.

Clinical uses of Serum Estradiol levels :

Monitoring estradiol levels is important in evaluation of :

1. Normal sexual development (menarche)

2. Amenorrhea
3. Precocious puberty
4. Onset of menopause
5. Infertility in men and women (anovulation, amenorrhoea, dysmenorrhoea)
6. IVF( in vitro fertilization) because the timing of recovery of oocytes depends on follicular development, which in turn depends
on the estradiol level.

Increased Levels of Serum Estradiol are seen in:

Precocious puberty (female) ·
Decreased Levels of Serum Estradiol are seen in:
Male Gynaecomastia ·
Oral contraceptives ·
Liver disease ·
Ovarian failure
Ovarian tumors ·
Adrenal feminizing tumors

*** End Of Report ***

Conditions of Laboratory Testing & Reporting:
Test results released pertain to the sample, as received. Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 5 of 6
 PO No :PO2912835867-962

Name : Mr.ASHU Client Name : TATA 1MG OKHLA

Age/Gender : 21/Male Registration Date : 09/Feb/2025 03:05PM
Patient ID : OKH1940550 Collection Date : 09/Feb/2025 01:51PM
Barcode ID/Order ID : D17290234 / 11944435 Report Date : 09/Feb/2025 07:15PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method
be clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report
may vary depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal
purposes. Please mail your queries related to test results to Customer Care mall ID care@1mg.com

Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All
lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes.
Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the
information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be
vetted by a qualified doctor only.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 6 of 6
 Ensuring accuracy IN every single report
Following a 3-step review process:

Advanced systems & Experienced lab experts Each report undergoes

cutting-edge technology analyze and technicians conduct rigorous medical scrutiny & is
results with precision comprehensive reviews signed off by a doctor

Have concerns regarding the report?

Reach out to our care team at care@1mg.com
or chat with us
CONNECT NOW >

Accurate Testing, Assured Quality: Diagnostics Precision

Stringent quality control Cutting-edge technology Experienced lab staff

Measures meeting Robust healthcare systems 30+ medical professionals
international norms of safety equipped with calibrated & with a collective
guidelines well-maintained machinery experience of 200+ years

Verified test procedures External assessments Trained phlebotomists

Highly standardized test Thorough third-party Ensuring smooth sample
procedures following CLSI* assessment by authorized collection experience &
guidelines experts pre-analytical precision

Claim FREE doctor consultation

Watch how
Consult top doctors from
the comfort of your home
we take care of
your sample
SCHEDULE NOW>

Get Second Opinion Order Medicines EXPLORE NOW >

Explore Financial Need Help?

Book Lab Tests
Support & more 1800-102-1618

*Clinical & Laboratory Standards Institute T&C Apply

 Are you getting
enough OMEGA 3
to protect your heart?
Because 80%^ of people don’t!

Choose Tata 1mg Salmon Omega 3

for a Healthier Heart

LDL

Reduces Improves Reduces

Triglyceride Levels Good Cholesterol Inflammation

Get Optimal Requirement#

of Omega 3 in 1 Capsule

EPA DHA Fish Oil

180 mg 120 mg 1000 mg

Why Choose Us?

50% Higher Absorption+

with Triglyceride form 50% Lower
Saturated Fats*
Every batch
Tested and Certified

Upto 30% off Shop Now

^ Stark KD, et al, progress in Lipid Research 2016 | * Compared with competing products
+ Reference from NCBI published article on comparative bioavailability | # Optimal requirement of Omega-3 as mentioned by National Institutes of Health. Dietary Supplement Label Database. 2015.